{
  "retracted": false,
  "timestamp": 1529712000000,
  "updates": [
    {
      "timestamp": 1574854413668,
      "identifier": {
        "doi": "10.1007/s00277-018-3403-9"
      },
      "type": "correction"
    }
  ],
  "identifier": {
    "doi": "10.1007/s00277-018-3380-z"
  },
  "journal": "Annals of Hematology",
  "publisher": "Springer Science and Business Media LLC",
  "title": "Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study"
}
